NP-G2-044 Monotherapy for Solid Tumor Malignancies

"Since 2021, NP-G2-044 Monotherapy has been subject to ongoing exploration. Initially studied in a 100 patient trial funded by Novita Pharmaceuticals, Inc., the drug successfully passed through Phase 1 & 2 of clinical trials and is now supported by one active study conducted under their sponsorship."

"This medical trial is being administered in 15 locations, such as the University of Kansas Cancer Centre located in Fairway, Atlantic Health System - Morristown Medical Center found in Morrisstown and University of Arkansas for Medical Sciences located in Little Rock."

"Currently, 1 clinical trial is underway for NP-G2-044 Monotherapy with no Phase 3 studies in progress. While most of the research centres are situated in Tucson, Arizona, other locations across 15 cities have also committed to conducting medical trials on this drug."

"This study's primary objective, to be evaluated within 30 days of the last dose administered, is to gain preliminary insights into NP-G2-044's efficacy when coupled with anti-PD-1 therapy as measured by RECIST 1.1. Auxiliary goals include characterizing the drug combination's antitumor activity via iRECIST and analyzing pharmacokinetics data such as area under plasma concentration curves (AUC) and time to peak plasma concentrations (Tmax)."

"Correct. Clinicaltrials.gov verifies that this medical experiment, which was first advertised on December 7th 2021, is proactively enlisting participants. A total of 100 individuals are needed to be enrolled from 15 different locations."

"Yes, the latest information on clinicaltrials.gov affirms that recruitment for this study is still ongoing since its initial posting date of December 7th 2021. In order to complete their research goals, 100 individuals must be recruited from 15 different centres."